475 related articles for article (PubMed ID: 25257673)
1. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease.
Kong WX; Ma FY; Fu SL; Wang W; Xie CH; Zhang YY; Gong FQ
World J Pediatr; 2019 Apr; 15(2):168-175. PubMed ID: 30809758
[TBL] [Abstract][Full Text] [Related]
3. Persistent endothelial damage after intravenous immunoglobulin therapy in Kawasaki disease.
Sakurai Y; Takatsuka H; Onaka M; Takada M; Nishino M
Int Arch Allergy Immunol; 2014; 165(2):111-8. PubMed ID: 25401215
[TBL] [Abstract][Full Text] [Related]
4. [Expression of sICAM-1 in children with intravenous immunoglobulin-resistant Kawasaki disease].
Liu F; Ding Y; Yin W
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Dec; 15(12):1109-12. PubMed ID: 24342209
[TBL] [Abstract][Full Text] [Related]
5. [Risk factors for coronary artery lesions in children with Kawasaki disease].
Li Y; Wang XM; Liu YL; Shi K; Yang YF; Guo YH
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Dec; 14(12):938-41. PubMed ID: 23234782
[TBL] [Abstract][Full Text] [Related]
6. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
[TBL] [Abstract][Full Text] [Related]
7. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
8. A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease.
Wei M; Huang M; Chen S; Huang G; Huang M; Qiu D; Guo Z; Jiang J; Zhou X; Yu Q; Guo Y; Fu L; Gao W; Li F
Pediatr Cardiol; 2015 Aug; 36(6):1166-72. PubMed ID: 25812827
[TBL] [Abstract][Full Text] [Related]
9. Association of lower eosinophil-related T helper 2 (Th2) cytokines with coronary artery lesions in Kawasaki disease.
Kuo HC; Wang CL; Liang CD; Yu HR; Huang CF; Wang L; Hwang KP; Yang KD
Pediatr Allergy Immunol; 2009 May; 20(3):266-72. PubMed ID: 19438983
[TBL] [Abstract][Full Text] [Related]
10. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
Yoshimura K; Kimata T; Mine K; Uchiyama T; Tsuji S; Kaneko K
J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
[TBL] [Abstract][Full Text] [Related]
11. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease.
Chang LS; Lo MH; Li SC; Yang MY; Hsieh KS; Kuo HC
Oncotarget; 2017 Jan; 8(2):2044-2052. PubMed ID: 27893416
[TBL] [Abstract][Full Text] [Related]
12. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of 942 cases of Kawasaki disease].
Zhang W; Li Q; Zhao XD; Tang XM; Wang XG; Wang M; Wu DQ; Ou Q; Yang XQ
Zhonghua Er Ke Za Zhi; 2006 May; 44(5):324-8. PubMed ID: 16780705
[TBL] [Abstract][Full Text] [Related]
15. Difference in Risk Factors for Subtypes of Acute Cardiac Lesions Resulting from Kawasaki Disease.
Yamashita M; Ae R; Yashiro M; Aoyama Y; Sano T; Makino N; Nakamura Y
Pediatr Cardiol; 2017 Feb; 38(2):375-380. PubMed ID: 27878631
[TBL] [Abstract][Full Text] [Related]
16. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
17. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
[TBL] [Abstract][Full Text] [Related]
18. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
19. Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.
Li W; Zhang L; Wang Z; He X; Lin H; Wang Y; Yuan J; Xie X; Zhang X; Qin Y; Huang P
Int J Clin Pract; 2022; 2022():2726686. PubMed ID: 35989868
[TBL] [Abstract][Full Text] [Related]
20. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease.
Hu P; Jiang GM; Wu Y; Huang BY; Liu SY; Zhang DD; Xu Y; Wu YF; Xia X; Wei W; Hu B
Clin Chim Acta; 2017 Aug; 471():76-80. PubMed ID: 28526535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
